HEC Pharm Awaits Fate As Novartis Petitions On US Gilenya Victory

Novartis is sticking to its plan to continue fighting HEC Pharm in court, after it recently lost a key decision for its Gilenya (fingolimod) blockbuster treatment for multiple sclerosis.